Novo Nordisk is navigating a pivotal moment defined by two starkly different timelines. On one front, the oral version of Wegovy is gaining traction at a pace that has caught the market’s attention. On the other, the company’s next-generation contender, CagriSema, remains stuck in a regulatory queue that won’t be resolved until late 2026. The 30-day rally of 19.52% that brought shares to €43.50 on Friday — despite a 1.20% daily dip — reflects the optimism around the pill’s rollout, yet the stock still sits 28.92% below its 52-week high of €61.20.
The oral 25-mg Wegovy formulation has been a bright spot. Since its US launch in January, over three million prescriptions have been written, with weekly new scripts now exceeding 200,000. In the first four months alone, more than a million Americans started taking the pill. International expansion is already underway: from July 6, 2026, it will be sold through private pharmacies in the UK, where more than 60,000 pre-orders have been placed. Additional demand support comes from the US “Medicare GLP-1 Bridge” programme, which, effective July 1, caps monthly copayments at $50 for eligible obesity patients.
The rally’s other pillar is chart-based. The stock has climbed 12.33% above its 50-day moving average of €38.72 and now sits 6.62% above the 200-day average of €40.80. But the Relative Strength Index has climbed to 71.2, pushing into overbought territory — a warning that the move may be ahead of fundamentals.
Those fundamentals hinge on CagriSema, the amylin-GLP-1 combination filed with the FDA in December 2025. A decision is not expected until the fourth quarter of 2026. In the REDEFINE 4 study, CagriSema delivered a 23% weight loss but failed to demonstrate statistical non-inferiority to Eli Lilly’s Zepbound at the 15mg dose after 84 weeks. That mixed result is the key uncertainty investors must weigh against the current technical strength. Bullish arguments point to fresh diabetes data from the REIMAGINE programme, presented at the American Diabetes Association meeting this year, which showed superior blood sugar control and weight reduction versus monotherapy — data that could help shape a favourable FDA label.
Competitive pressures are mounting from multiple directions. Eli Lilly’s Foundayo, launched in April 2026, is gaining market share. More concerning for Novo’s long-term story is Lilly’s triple-agonist Retatrutid, which has achieved weight loss exceeding 30% in trials. Market share estimates already paint a stark picture: Novo now holds roughly 40% of the GLP-1 market, while Lilly commands 60%. Morgan Stanley analyst Thibault Boutherin continues to prefer Lilly on the back of superior efficacy data and the intensifying threat from generics.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Generics are already eroding Novo’s position in secondary markets. In Canada, copycat products have captured 60% of the semaglutide market, compounded by a 12% price cut that took effect July 1. The company’s €192.69 billion market capitalisation belies this fragility outside the US.
Technical and fundamental risks are not limited to the pipeline. The FDA has proposed removing semaglutide from the 503B bulk-compounding list, a move that could curb unofficial copycat preparations in the US and steer patients back to branded products. But a recent Phase 3 Alzheimer’s study of oral semaglutide failed, dimming hopes for expansion beyond metabolic indications — a growth avenue that had been priced in by some bulls.
What happens next depends on two upcoming catalysts. From July 11 to 15, Novo Nordisk presents new haemophilia data at the ISTH congress. Then on August 5, the half-year report will reveal whether the full-year guidance of -4% to -12% adjusted revenue growth at constant exchange rates remains realistic. That figure will be critical in judging whether the current rally — which lifted the stock from its 52-week low of €30.25 — can sustain itself or was merely a relief bounce.
For now, the oral Wegovy rollout provides a tangible narrative of growth, while the CagriSema decision, expected in the fourth quarter, looms as a binary event. Between these two poles, the stock is likely to oscillate, with the 50-day moving average at €38.72 serving as a potential floor if sentiment turns before a clear catalyst arrives.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from July 5 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 5.
Novo Nordisk: Buy or sell? Read more here...
